Olema Pharmaceuticals, Inc.
OLMA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$6.41
KIRA · Stoqly’s AI analyst, in plain words
- Olema Pharmaceuticals, Inc. lost $162M in fiscal 2025.
Market cap
$670M
P/E
—
Revenue
—
Net income
−$162M
Free cash flow
—
Operating margin
—
Olema Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$162M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Olema Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Olema Pharmaceuticals, Inc.
- CIK
- 0001750284
Olema Pharmaceuticals, Inc. · OLMA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$71.1M | −$105M | −$96.7M | −$129M | −$162M |
| Diluted EPS | −$1.80 | −$2.62 | −$2.14 | −$2.20 | −$1.87 |
| Cash | |||||
| Cash from operations | −$50.7M | −$82.1M | −$83.7M | −$104M | −$147M |
| Capital expenditure | $1.6M | $0.4M | — | $0.2M | — |
| Free cash flow | −$52.3M | −$82.4M | — | −$105M | — |
| Share count change | 462.9% | 1.2% | 13.1% | 29.8% | 48.1% |
| Debt and strength | |||||
| Cash and short-term investments | $287M | $204M | $262M | $434M | $505M |
| Shareholders' equity | $285M | $198M | $254M | $409M | $479M |
| Current ratio | 32.2x | 12.6x | 12.3x | 10.5x | 10.0x |
| Returns and quality | |||||
| Return on equity | −22.8% | −43.5% | −42.8% | −39.1% | −36.6% |
| Return on tangible equity | −25.0% | −53.0% | −38.1% | −31.7% | −33.9% |
| Altman Z'' | 29.7 | 10.8 | 11.2 | 10.7 | 9.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$24.7M
6 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Olema Pharmaceuticals, Inc. · OLMA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.41 a share, the company is worth $670M.
Source: SEC EDGAR XBRL filings (CIK 0001750284). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.